Assembly Biosciences registers Phase 2 trial of ABI-6250 for chronic hepatitis D
A newly listed study will test the tablet drug ABI-6250 against chronic hepatitis D virus infection at 22 sites across 11 countries.
- Assembly Biosciences registered "A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection" (NCT07762027), which is designed to assess safety, pharmacokinetics, and efficacy of ABI-6250 in participants with Chronic Hepatitis D Virus Infection1. The study is listed as not yet recruiting, with an estimated start of 2026-10 and estimated primary completion in 2027-061, and it plans to enroll 80 participants across four experimental treatment arms, each testing ABI-62501. Dosing is set as once daily tablet dosing for 48 weeks, with one regimen starting at the Day 1 visit and another starting at the Week 16 visit1, and the trial will run at 22 sites in 11 countries including France, Georgia, Germany, Italy, Moldova, New Zealand, Pakistan, Romania, Spain, Ukraine, and the United Kingdom1.
Fact check notes
- Checker's noteThe claim that Assembly Biosciences 'had one registry update this week' is not supported by the source, which contains no information about update frequency or timing relative to the current week.
- Sentence removed
Assembly Biosciences had one registry update this week, a new Phase 2 study of its hepatitis D candidate.
unsupported: The source gives no information about the number of registry updates or timing relative to 'this week'; this appears to be an editorial addition not supported by the document.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.